ACRX - AcelRx Pharma rises8% on positive data from post-operative pain management therapy
- AcelRx Pharma ( NASDAQ: ACRX ) is trading ~8% higher aft er its sublingual sufentanil tablets for post-operative pain management showed lower pain scores, fewer rescue doses and had a shorter hospital stay in patients compared to those receiving continuous femoral nerve block.
- The study, which was conducted at the University of Padova in Italy, analyzed a total of 71 patients with respect to quality of postoperative pain management following total knee arthroplasty.
- Investigators analyzed data from 50 patients who received sufentanil sublingual tablets postoperatively versus a control group of 21 patients who were treated according to standard pain management protocol with continuous femoral nerve block, the company said.
For further details see:
AcelRx Pharma rises8% on positive data from post-operative pain management therapy